Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.33 |
| ▸ | WDR77 | Q9BQA1 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4986192 | 0.90 | GRM2 (0.40) | KMT2AGRM2ALDH1A1S1PR5HPGD | |
| SCHEMBL4989112 | 0.82 | OPRM1 (0.35) | OPRM1OPRD1OPRK1 | |
| SCHEMBL4989498 | 0.78 | MAPT (0.39) | KMT2AALDH1A1KDM4EHPGDPOLB | |
| SCHEMBL4985154 | 0.78 | GRM5 (0.36) | KMT2AALDH1A1OPRM1OPRD1OPRK1 | |
| SCHEMBL4988534 | 0.78 | OPRM1 (0.43) | GRM2OPRM1OPRD1OPRK1 | |
| SCHEMBL4989567 | 0.78 | TSHR (0.39) | KMT2AALDH1A1KDM4E | |
| SCHEMBL4985381 | 0.76 | PARP1 (0.33) | GRM2ALDH1A1L3MBTL1 | |
| SCHEMBL4988945 | 0.76 | KDM4E (0.40) | KMT2AGRM2ALDH1A1KDM4EHPGD | |
| SCHEMBL4989374 | 0.76 | HRH3 (0.43) | KMT2AOPRM1OPRD1OPRK1 | |
| SCHEMBL4982815 | 0.76 | MEN1 (0.45) | KMT2AALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | RENOVIS, INC. | 2008-02-14 | — | — | US | claimed |
| US-7297700-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. (US) | 2007-11-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | P2RX7, P2RX3, P2RX2 | KMT2A 4614/4885GRM2 332/4885ALDH1A1 3640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.